Greg Serbarinov
About Greg Serbarinov
Greg Serbarinov is an Associate Director at Bristol Myers Squibb in Summit, New Jersey, specializing in predicting adverse drug-drug interactions using advanced machine learning techniques.
Current Company and Role
Greg Serbarinov currently holds the position of Associate Director at Bristol Myers Squibb, based in Summit, New Jersey, United States. He has been in this role since September 2019, contributing to the company's mission through his expertise in predictive modeling and data analysis.
Previous Experience at Morgan Stanley
Before joining Bristol Myers Squibb, Greg Serbarinov worked at Morgan Stanley as a Lead Data Scientist. He was with the financial services firm for six years, from 2013 to 2019, in the Greater New York City Area. During his tenure, he specialized in advanced data analytics and machine learning techniques.
Career at IBM
From 2010 to 2013, Greg Serbarinov served as a Senior IS Consultant at IBM in the Austin, Texas Area. Over this three-year period, he was involved in various projects that leveraged his skills in system consulting and data solutions, contributing to the company's technological advancements.
Education and Specialization
Greg Serbarinov holds a Master of Science degree in Physics from Saint Petersburg State University. His academic background provides a strong foundation for his specialized work in predicting adverse drug-drug interactions and utilizing graph convolutional networks to model polypharmacy side effects.
Expertise in Machine Learning and Data Mining
Greg Serbarinov has in-depth expertise in using machine learning models and data mining techniques for transforming patient safety data into actionable insights. He works with multimodal graphs of protein-drug interactions to enhance predictive models, applying neural embedding of semantic predications to forecast adverse drug-drug interactions.